Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties
Alm. Brand – Report on trading in Alm. Brand A/S shares by executives and their related parties
Pursuant to article 19 of the EU Regulation 596/2014 and according to a power of attorney given by Rasmus Werner Nielsen, Alm. Brand A/S is required to file information on trading in shares in Alm. Brand A/S or other securities related to these shares by executives and their related parties.
Please see attached report.
Contact
Please direct any questions regarding this announcement to:
Senior Investor Relations Officer Mikael Bo Larsen, Mobile no. +45 51 43 80 02
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
PHARMANOVIA ENTERS NEW CHEMICAL ENTITY LICENSING AGREEMENT WITH STEALTH BIOTHERAPEUTICS TO MARKET AND FURTHER DEVELOP A POTENTIAL NOVEL TREATMENT FOR BARTH SYNDROME30.5.2023 15:25:24 CEST | Press release
Basildon, UK, May 30, 2023 (GLOBE NEWSWIRE) -- PRESS RELEASE - FOR BUSINESS & TRADE MEDIA ONLY THE AGREEMENT COVERS RIGHTS FOR ELAMIPRETIDE FOR BARTH SYNDROME IN THE EU, NORWAY, SWITZERLAND, UK, ICELAND, AND MIDDLE EAST & NORTH AFRICA (MENA) TERRITORIESTHERE ARE NO CURRENT APPROVED TREATMENTS FOR BARTH SYNDROMETHIRD NEW CHEMICAL ENTITY DEAL FOR PHARMANOVIA, EXPANDING PORTFOLIO IN CARDIOLOGY AND RARE DISEASES Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its cardiology portfolio through a new licensing agreement with US-based biopharmaceutical company, Stealth BioTherapeutics Inc. The agreement gives Pharmanovia the licensing rights to elamipretide for Barth syndrome in Europe and MENA. This is a significant milestone as ongoing studies indicate that elamipretide has the potential to improve the quality of life for people with Barth syndrom
Golar releases its 2022 Environmental, Social and Governance report30.5.2023 15:23:39 CEST | Press release
Golar LNG Limited (“Golar”) is pleased to announce that it has issued its 2022 Environmental, Social and Governance (“ESG”) report. This comprehensive report describes Golar’s important role in advancing the global energy transition to a lower carbon future - championing LNG as a transition fuel in partnership with renewables, and as a reliable alternative for those in need of energy security today. Our 2022 ESG report is attached and will also be posted to our website. Forward-Looking Statements This press release contains forward-looking statements (as defined in Section 21E of the Securities Exchange Act of 1934, as amended). All statements, other than statements of historical facts, that address activities and events that will, should, could or may occur in the future are forward-looking statements. Words such as “may,” “could,” “should,” “would,” “expect,” “plan,” “anticipate,” “intend,” “forecast,” “believe,” “estimate,” “predict,” “propose,” “potential,” “continue,” or the negat
Awilco Drilling PLC: Notice of Annual General Meeting 202330.5.2023 15:15:00 CEST | Press release
The Annual General Meeting of Awilco Drilling PLC will be held Monday 26 June 2023 at 12:00 noon (UK time), at the offices of Awilco Drilling on 2 Kingshill Park, Venture Drive, Arnhall Business Park, Westhill, Aberdeen, AB32 6FL, UK. The notice including agenda for the General Meeting is attached to this disclosure. The notice will be sent by mail or e-mail to the shareholders. The notice and appendices have been made available on our website www.awilcodrilling.com. Aberdeen, 30 May 2023 For further information please contact: Eric Jacobs, Interim CEO Phone: +44 1224 737900 Cathrine Haavind, Investor Relations Phone: +47 93 42 84 64 Email: ch@awilcodrilling.com This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment AWDR AGM Notice 2023
Ekstraordinære indfrielser (CK 93)30.5.2023 15:12:56 CEST | pressemeddelelse
I medfør af kapitalmarkedsloven § 24, oplyser DLR Kredit hermed om ekstraordinære indfrielser pr. fredag den 26. maj 2023. Oplysningerne fremgår af vedhæftede fil. Denne meddelelse er offentliggjort med henblik på opfyldelse af transparensdirektivets krav om offentliggørelse. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Spørgsmål kan rettes til: Head of Rating & IR Jakob Kongsgaard Olsson tlf. nr. 33 42 07 06. Med venlig hilsen DLR Kredit A/S Vedhæftet fil ck93-2023-05-26
Meddelelse nr. 6, 2022/2330.5.2023 15:06:54 CEST | pressemeddelelse
Halvårsrapport Pr. 31. marts 2023 Investeringsselskabet Luxor A/S’ bestyrelse har dags dato godkendt halvårsrapporten pr. 31. marts 2023. 2. kvartal 2022/23: Basisindtjeningen er kr. 12,2 mio. (kr. 13,6 mio.).Koncernens resultat før skat er kr. 12,1 mio. (kr. 35,3 mio.). Kvartalets resultat før skat er kr. 0,1 mio. lavere end basisindtjeningen, hvilket skyldes: kr. -2,9 mio. fra dagsværdiregulering af renteswaps og gæld til realkreditinstitutter.kr. 2,8 mio. fra dagsværdiregulering af finansielle aktiver. Halvåret 2022/23: Basisindtjeningen er kr. 21,7 mio. (kr. 27,3 mio.).Koncernens resultat før skat er kr. 20,3 mio. (kr. 58,0 mio.). Halvårets resultat er kr. 1,4 mio. lavere end basisindtjeningen, primært som følge af: kr. -5,0 mio. fra dagsværdiregulering af renteswaps og gæld til realkreditinstitutter samt omkostninger til optagelse af realkreditlån.kr. 3,6 mio. fra dagsværdiregulering af finansielle aktiver. Forventet basisindtjening 2022/23: For regnskabsåret 2022/23 forventes på